EPS in Biological Technology
Navigation Links
EPS in Biological Technology
Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
PITTSBURGH, July 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced its financial results for the three and six months ended June 30, 2009. Financial Highlights Adjusted diluted EPS, which excludes the impact of certain purchase acc...ST. LOUIS, July 23 /PRNewswire-FirstCall/ --Sigma-Aldrich Corporation (Nasdaq: SIAL ), a leading Life Science and High Technology company, reported second quarter 2009 diluted EPS of $0.68 compared to $0.70 in the second quarter of 2008. For the six months ended June 30, 2009, reporte...
Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets
PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD ) today reported earnings for its first quarter ended March 31, 2009 of $0.63 per diluted share versus $0.76 per diluted share in the first quarter of 2008 (or $0.73 per diluted share after excluding the centralized ECG ...First-Quarter 2009 Highlights: - GAAP diluted EPS increased 16.0 percent to $0.58 from $0.50 in first-quarter 2008 - Diluted EPS, excluding $0.05 in amortization of intangible assets from the 2003 spin-off, increased 14.5 percent to $0.63 from $0.55 in first-quarter 2008 - Total net...
Reaffirms Adjusted Diluted EPS Guidance of $0.90 to $1.10 for 2009 and $1.50 to $1.70 for 2010 PITTSBURGH, Feb. 19 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced its financial results for the three and twelve months ended Dec. 31, 2008 and reaffirmed adjusted diluted EP...
ST LOUIS, Feb. 11 /PRNewswire-FirstCall/ -- Sigma-Aldrich, a leading Life Science and High Technology company, reported that its fourth quarter 2008 diluted EPS grew by 6% to $0.68 from $0.64 in the same quarter of 2007. Reported sales of $510 million in the fourth quarter 2008 declined...
Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Increases 2008 Adjusted EPS Guidance to $0.64 - $0.67 from Prior Range of $0.47 - $0.53 Reaffirms Adjusted EPS Guidance of $0.90 - $1.10 for 2009 and $1.50 - $1.70 for 2010 PITTSBURGH, Oct. 30 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE:...ST. LOUIS, Oct. 21 /PRNewswire-FirstCall/ -- HIGHLIGHTS: 2008 Results (all percentage comparisons are to comparable periods in 2007): -- Q3 2008 Sales Driven By Consistent Research Sales Gain: Q3 2008 sales increased 7.4% to $540.6 million. Currency added 3.1% to organic growth ...
ST. LOUIS, July 22 /PRNewswire-FirstCall/ -- HIGHLIGHTS: 2008 Results (all percentage comparisons are to comparable periods in 2007): -- Q2 2008 Sales Set New Quarterly Record: Q2 2008 sales reached another new quarterly high of $580.7 million, an increase of 14.4%. All four ...
ST. LOUIS, April 22 /PRNewswire-FirstCall/ -- HIGHLIGHTS: 2008 Results (all percentage comparisons are to comparable periods in 2007): -- Q1 2008 Sales Set New Quarterly Record: Q1 2008 sales reached a new quarterly high of $569.6 million, an increase of 14.9%, with all ...
- 4Q EPS Grows 21.8% to $0.72 on 19.8% Revenue Growth - PRINCETON, N.J., Jan. 30 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today reported earnings for its fourth quarter ended December 31, 2007 of $0.78 per diluted share and full-year EPS of $2.71; both periods include a $0.06...
WALTHAM, Mass., Oct. 25 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO ), the world leader in serving science, reported that revenues increased to a record $2.40 billion in the third quarter of 2007 (largely as a result of the November 2006 merger with Fisher Scientific), ...
Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
2007 Diluted EPS Forecast Raised $.05 to $2.25 to $2.35. ST. LOUIS, Oct. 23 /PRNewswire-FirstCall/ -- HIGHLIGHTS: Sales, Income and EPS Results (all percentage comparisons are to comparable periods in 2006): -- Strongest Quarterly Sales Growth in 2007: Q3 2007 sales growth ...Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... - 0.2 - Numerator for basic eps 44.1 (79.0) 257.7 49.6 ... - - (2.2) Numerator for diluted eps 44.1 (79.0) 257.7 47.4 ...have been excluded from the calculation of diluted eps because their exercise prices exceeded Shire plc's...Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
...9 57,128 (47%) 69,066 116,656 (41%) Reported Diluted eps 0.26 0.46 (43%) 0.59 0.90 (34%) A...67 72,708 18% 164,890 140,914 17% Adjusted Diluted eps $0.73 $0.59 24% $1.41 $1.09 29% ...Caliper Life Sciences Reports Second Quarter 2009 Results
... 2009 2008 2009 2008 ---- ---- ---- ---- GAAP eps - Basic $(0.08) $(0.14) $(0.22) $(0.35) Adjustments: Acquisition related intangible amortization(1) ...Sanofi-aventis Announces Second Quarter 2009 Results
... 2009 second-quarter growth of adjusted eps excluding selected items of 17.2% at constant exch... Guidance raised: growth in adjusted eps excluding selected items of around 10% at constant... (3) Closing expected in Q3 2009 (4) Adjusted eps excluding selected items, at constant exchange rat...Schering-Plough Reports Financial Results for 2009 Second Quarter
...piratory joint venture with Merck. 4/ Diluted eps for the three months ended June 30, 2009 is calcul...tock were excluded from the computation of diluted eps because their effect would have been antidilut...or the six months ended June 30, 2009, diluted eps is calculated based on net income and average dilu...China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results
... FY 2009 FY 2008 Diluted Diluted Non-GAAP Net income and diluted eps Net Income EPS(1) Net Income EPS(1) Adjusted Amount 16,874,889 $0.99 14,176,244 $0.83 Adjustments Non-cash ga...New Report Just Published: World Endoscopy Systems Market Report
... ViaDux Healthcare is Now Solos Endoscopy II-50 Advanced Sterilization Obtains FDA Clearance II-50 STERIS Obtains FDA Approval For Reliance eps II-50 Solos Endoscopy Files For FDA Clearance of OvaScope(TM) and MastaScope(TM) II-50 ACMI Establishes GSS Business Unit II-50 Xillix...Solutia Reports First Quarter 2009 Results
...--------------- --- Adjusted earnings for adjusted eps $(5) ---------------------------------- ...------------------ ----- Adjusted eps (0.05) ------------ ...Shire begins the year with a strong performance
... ________ ________ Numerator for basic eps 213.6 128.6 Int... ________ ________ Numerator for diluted eps 222.0 132.0 ...have been excluded from the calculation of diluted eps because their exercise prices exceeded Shire plc's...Caliper Life Sciences Reports First Quarter 2009 Results
... March 31, 2009 2008 GAAP eps - Basic $(0.14) $(0.21) Adjustments: Acquisition related intangible amortization (1) ...ViroPharma Incorporated Reports First Quarter 2009 Financial Results
...s. Under this new accounting method, the Company's eps and net (loss) income calculated in accordance wit...nder this new accounting method, the Company's eps and net (loss) income calculated in accordance wit... 4. Other items - Non-GAAP net income and diluted eps exclude other unusual or non-recurring items that ...China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results
... 28.6% to $14.1 Million, with Net Income was $0.9 Million and Diluted eps of $.03 - 2008 Revenues Increased 23.5% to $59.1 Million vs. 2007 ...o 20.1% - 2008 Net Income Increased 13.7% to $4.1 Million with Diluted eps of $0.13 - 2008 Cash Flow from Operations was $5.9 million ...Yongye Biotechnology Announces Preliminary Results for its Fiscal Quarter Ended March 31, 2009
.... Net income is expected to be $2.75 million to $3.0 million, up approximately 145% to 168% from the corresponding previous quarter, and fully diluted eps on weighted average number of shares is expected to be $0.13 to $0.15. Yongye sold over 95,000 units of its plant nutrient product in the quart...GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business
...ion costs, the transaction is expected to result in minor earnings per share (EPS) dilution for GSK in 2009 (less than 1%) and to be 1-2% accretive to eps in 2010. The transaction has been approved by the Stiefel stockholders. Closing of the transaction is conditional upon certain matters including...Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
...on doses of Healive(R) in 2008, up from 5.12 million in 2007 -- Record full year net income growing of 5% to $8.01 million -- Full year eps is $0.19 -- Cash and cash equivalents increased 93% to $32.9 million, compared to the beginning of 2008, due to an increase in operation pr...Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
...on doses of Healive(R) in 2008, up from 5.12 million in 2007 -- Record full year net income growing of 5% to $8.01 million -- Full year eps is $0.19 -- Cash and cash equivalents increased 93% to $32.9 million, compared to the beginning of 2008, due to an increase in operation pr...Gen-Probe Completes Acquisition of Tepnel Life Sciences
...res This announcement contains certain financial measures that are not calculated in accordance with U.S. GAAP, including non-GAAP EPS. Non-GAAP eps excludes all non-cash charges such as intangible amortization and stock compensation expense, as well as transaction expenses. Gen-Probe's management...China Biologic Products Announces Strong 2008 Results
...e 1 for a reconciliation of Net Income and eps to exclude SBC. Financial Condition ...ted Diluted Net Income (Loss) Diluted eps Net Income eps Net Income EPS Adjusted Amount - Non-GAAP ...China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
... $6.5 million $2.1 million +209.5 % GAAP eps ($0.13) ($0.05) -60 % Adjusted eps (Fully Diluted)* $0.17 ($0.05) ...$28.6 million $8.6 million +232.7 % GAAP eps $0.54 $0.21 ...BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
... Income (Loss) $ 1,119 $(6,590) $(3,442) $(11,635) GAAP eps $ 0.03 $ (0.06) $ (0.10) $ (0.12) Stock... Income (Loss) $ 3,777 $(5,282) $ 7,242 $ (8,994) Non GAAP eps $ 0.09 $ (0.17) $ 0.19 $ (0.32) ...Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results
... December 31, December 31, 2008 2007 2008 2007 GAAP eps - Basic $(0.95) $(0.12) $(1.42) $(0.51) Adjustments: Share-based compensation expense (1) ......anced through a diversity of research approaches and sharing of IP, technologies, partnerships and other key assets -- Transaction expected to be eps accretive in the first year after closing BASEL and SOUTH SAN FRANCISCO, March 12 /PRNewswire-FirstCall/ -- Roche (SWX: ROG.VX; RO.S) and Genente...
Mindray Announces 2008 Fourth Quarter and Full Year Results
... 36.2 25.3 43.3% Diluted eps 0.28 0.19 48.7% Non-GAAP Diluted eps (1) 0.32 0.22 44.4... 144.5 90.2 60.2% Diluted eps 0.96 0.69 ...Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge
...et loss $(2,430) $54 $(18) $(2,394) GAAP eps $(1.62) $0.04 $(0.01) $(1.59) Adjusted eps $0.21 $(0.01) $0.20 Boston Scien......sh flow increased more than $50 million to $175 million. In total, 2008 adjusted results reflect the company's strong fundamentals with fully diluted eps growth of 11.7% and EBITDA increasing more than 14%," he said. Full Year 2009 Outlook The following outlook is based on adjusted results and ...
GlaxoSmithKline Reports Q4 and Year End Results 2008
...pharmaceutical group's results as "robust" in a year that was "always going to be challenging". GSK also announced that it will cease providing eps guidance, to allow a focus on longer term strategic goals. Describing 2008 as a strategic turning point for GSK Mr Witty said: "We started to m...Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
... Second quarter eps of $0.44 -- increase of 110% from prior year ...econd Quarter Highlights Record eps of $0.44, representing an increase of 110% from se... First Six Months Highlights eps of $0.87, representing an increase of 142% and 358...Other TagsBridBridBridBridBridBridRailRailMinimize
Breaking Biology News(10 mins):The impact of the diffusion of maize to the Southwestern United States 2Study reveals how Arctic food webs affect mercury in polar bears 2MSU researcher unveils new approach to treat lower back pain 2Air Pollution May Cause Appendicitis 3A Study 58869 1Air Pollution May Cause Appendicitis 3A Study 58869 2Air Pollution May Cause Appendicitis 3A Study 58869 3UCSF Scientist Receives Nobel Prize in Physiology or Medicine 58864 1UCSF Scientist Receives Nobel Prize in Physiology or Medicine 58864 2UCSF Scientist Receives Nobel Prize in Physiology or Medicine 58864 3CCMC Celebrates Case Management Week 28Oct 11 17 29 With Second Annual Patricia McCollom Scholarship 58859 1CCMC Celebrates Case Management Week 28Oct 11 17 29 With Second Annual Patricia McCollom Scholarship 58859 2
Breaking Medicine News(10 mins):Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 2Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 3Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 4Health News:Hissey Kientz, LLP Warns Birth Control Pill Users Of Increased Health Risks To Those Who Have Or Are Taking YAZ or YASMIN 2Health News:Hissey Kientz, LLP Warns Birth Control Pill Users Of Increased Health Risks To Those Who Have Or Are Taking YAZ or YASMIN 3Health News:Hissey Kientz, LLP Warns Birth Control Pill Users Of Increased Health Risks To Those Who Have Or Are Taking YAZ or YASMIN 4Health News:Okuma Real Help Machine Tool Giveaway Finalists Announced 2Health News:Late-breaking brain and behavior research presented at ACNP annual meeting this week 2
Other Contentsovaryovaryovaryovaryovaryovaryovaryosteocyteoverlappingoverlappingoverlappingoverlappingoverlappingoverlappingoverhangoverhangoverhangoviductovulationovulationovulationovulationovulation[0] Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance[0] Hissey Kientz, LLP Warns Birth Control Pill Users Of Increased Health Risks To Those Who Have Or Are Taking YAZ or YASMIN[0] Algeos Launches UK's First Private Podiatrist Loyalty Program[0] Okuma Real Help Machine Tool Giveaway Finalists Announced [0] Late-breaking brain and behavior research presented at ACNP annual meeting this week
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |